更新于：2024-11-04
Mupirocin
莫匹罗星
更新于：2024-11-04
概要
基本信息
简介莫匹罗星（Mupirocin）商品名CENTANY®，是一种小分子药物，通过抑制RNA合成酶治疗由革兰氏阳性细菌引起的脓疱病和其他皮肤感染。Mupirocin最初由GSK开发，1987年12月首次批准使用。CENTANY®软膏是一种局部药物，用于通过抑制细菌生长和阻止感染传播来治疗脓疱病。 |
药物类型 小分子化药 |
别名 Bactroban、Bactroban Nasal、Mupirocin (USP/INN) + [7] |
作用机制 Bacterial IRS抑制剂(细菌异硫氨酸-tRNA合成酶抑制剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H44O9 |
InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N |
CAS号12650-69-0 |
关联
76
项与 莫匹罗星 相关的临床试验Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads
Clinical effects of photodynamic therapy with Ondapench photosensitive antibacterial powder as photosensitiser compared with mupirocin ointment in the treatment of bacterial skin infections
SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults
100 项与 莫匹罗星 相关的临床结果
登录后查看更多信息
100 项与 莫匹罗星 相关的转化医学
登录后查看更多信息
100 项与 莫匹罗星 相关的专利（医药）
登录后查看更多信息
2,126
项与 莫匹罗星 相关的文献（医药）2024-11-01CYTOTHERAPY
The mesenchymal stromal cell secretome promotes tissue regeneration and increases macrophage infiltration in acute and methicillin-resistant Staphylococcus aureus-infected skin wounds in vivo
Article
作者: Rajesh, Aarthi ; Ju, Esther Da Eun ; Oxford, Kelly A ; Harman, Rebecca M ; Van de Walle, Gerlinde R
BACKGROUND AIMS:
The prevalence of chronic wounds continues to be a burden in human medicine. Methicillin-resistant Staphylococcus aureus (MRSA) is commonly isolated from infected wounds. MRSA infections primarily delay healing by impairing local immune cell functions. This study aimed to investigate the potential of mesenchymal stromal cell (MSC)-secreted bioactive factors, defined as the secretome, to improve innate immune responses in vivo. MSCs were isolated from the bone marrow of horses, which serve as valuable translational models for wound healing. The MSC secretome, collected as conditioned medium (CM), was evaluated in vivo using mouse models of acute and MRSA-infected skin wounds.
METHODS:
Punch biopsies were used to create two full-thickness skin wounds on the back of each mouse. Acute wounds were treated daily with control medium or bone marrow-derived MSC (BM-MSC) CM. The antibiotic mupirocin was administered as a positive control for the MRSA-infected wound experiments. Wounds were photographed daily, and wound images were measured to determine the rate of closure. Trichrome staining was carried out to examine wound tissue histologically, and immunofluorescence antibody binding was used to assess immune cell infiltration. Wounds in the MRSA-infected model were swabbed for quantification of bacterial load.
RESULTS:
Acute wounds treated with BM-MSC CM showed accelerated wound closure compared with controls, as illustrated by enhanced granulation tissue formation and resolution, increased vasculature and regeneration of hair follicles. This treatment also led to increased neutrophil and macrophage infiltration. Chronic MRSA-infected wounds treated with BM-MSC CM showed reduced bacterial load accompanied by better resolution of granulation tissue formation and increased infiltration of pro-healing M2 macrophages compared with control-treated infected wounds.
CONCLUSIONS:
Collectively, our findings indicate that BM-MSC CM exerts pro-healing, immunomodulatory and anti-bacterial effects on wound healing in vivo, validating further exploration of the MSC secretome as a novel treatment option to improve healing of both acute and chronic wounds, especially those infected with antibiotic-resistant bacteria.
2024-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Three-dimensional printed polyelectrolyte construct containing mupirocin-loaded quaternized chitosan nanoparticles for skin repair
Article
作者: Al-Musawi, Mastafa H ; Muslim, Rana Kadum ; Al-Musawi, Mastafa H. ; Almajidi, Yasir Qasim ; Issa, Anmar A. ; Mirhaj, Marjan ; Shahriari-Khalaji, Mina ; Issa, Anmar A
Despite substantial advancements in wound dressing development, effective skin repair remains a significant challenge, largely due to the persistent issue of recurrent infections. Three-dimensional printed constructs that integrate bioactive and antibacterial agents hold significant potential to address this challenge. In this study, a 3D-printed hydrogel scaffold composed of polyallylamine hydrochloride (PAH) and pectin (Pc), incorporated with mupirocin (Mp)-loaded quaternized chitosan nanoparticles (QC NPs) was fabricated. The primary objective of this study was to facilitate a controlled and sustained release of Mp via the QC NPs. The average size of QC-Mp nanoparticles was measured to be 66.05 nm and the average strand diameter and pore size of the 3D-printed construct were measured as 147.22 ± 5.83 and 388.44 ± 14.50 μm, respectively. The hemolysis rate of all scaffolds was below 2 %, indicating that they can be classified as non-hemolytic materials with sufficient blood compatibility. The PAH-Pc/QC-Mp scaffold exhibited significant antibacterial activity, enhanced cell viability in HaCat cells, sustained Mp release until day 7 (⁓60 %), and in-vivo wound healing promotion by stimulation of human keratinocytes. In conclusion, the proposed biocompatible construct demonstrates significant potential for the treatment of chronic and infected wounds by preventing infection and promoting accelerated wound healing.
2024-10-01AMERICAN JOURNAL OF INFECTION CONTROL
The efficacy of an alcohol-based nasal antiseptic versus mupirocin or iodophor for preventing surgical site infections: A meta-analysis
Review
作者: Hoffmann, Karen K ; Steed, Connie J ; Wenzel, Richard P ; Kremelberg, David
BACKGROUND:
Nasal decolonization of Staphylococcus aureus is a proven strategy to reduce surgical site infections (SSI). Recently updated guidelines expanded nasal decolonization beyond traditionally high-risk populations to include the option for alcohol-based antiseptics (ABAs). We assessed the efficacy of a novel ABA for reducing SSI compared to mupirocin and iodophor.
METHODS:
A literature search in Google Scholar, PubMed, MEDLINE, and Cochrane databases was completed of studies reporting SSI outcomes in hospitals using an ABA. Primary meta-analyses were conducted to analyze ABA clinical efficacy versus no intervention (7 studies); subanalyses compared the ABA to mupirocin (3 studies) or iodophor (2 studies).
RESULTS:
One hundred forty-seven nasal decolonization titles for SSI prevention were identified, of which 7 were accepted. In the studies selected, 16,212 patients were included: 7,983 (49.24%) control group, and 8,129 (50.14%) intervention group. Significant effect sizes (measured as odds ratios [ORs]) and z-scores were found in all 3 meta-analyses: (OR = 3.178, z = 4.743, P < .001) in ABA clinical efficacy, (OR = 4.110, z = 3.167, P < .01) in ABA versus mupirocin, and (OR = 3.043, z = 3.155, P < .01) in ABA versus iodophor. Funnel plots for each demonstrated a lack of bias.
CONCLUSIONS:
Statistically significant positive effects were identified in all 3 meta-analyses. An ABA appears to be a viable alternative to mupirocin or iodophors to reduce SSIs.
100 项与 莫匹罗星 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发感染 | 澳大利亚 | 1998-04-03 | |
| 革兰氏阳性细菌感染 | 中国 | 1993-01-01 | |
| 脓疱疮 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 14 | Hygiene education (Hygiene Education) | 膚艱鏇鹹選壓鏇範製壓(範廠蓋憲獵夢憲衊淵醖) = 窪壓網繭網鑰醖壓蓋窪 憲構膚艱醖鬱醖蓋範糧 (鏇鹽淵選選醖襯製積醖, 鬱齋壓齋觸鏇衊製廠範 ~ 獵積願蓋襯積糧繭夢餘) 更多 | - | 2024-06-25 | |
Sodium Hypochlorite+Mupirocin ointment (Hygiene Education and Decolonization) | 膚艱鏇鹹選壓鏇範製壓(範廠蓋憲獵夢憲衊淵醖) = 醖齋蓋構衊鬱壓鏇蓋構 憲構膚艱醖鬱醖蓋範糧 (鏇鹽淵選選醖襯製積醖, 遞餘構蓋夢範齋醖艱廠 ~ 蓋獵鹽廠鹹鹹鹹選憲範) 更多 | ||||||
临床4期 | 353,323 | (Arm 1: Routine Care (Mupirocin/CHG)) | 鹹醖選壓築獵夢夢齋壓(範獵蓋衊醖願襯鬱蓋膚) = 獵製壓獵襯願築蓋憲襯 鑰襯獵艱積遞蓋襯夢窪 (艱醖夢廠壓醖製積獵鬱, 積憲鏇築網選觸構衊網 ~ 蓋齋鹹鏇簾廠獵構鹹廠) 更多 | - | 2024-02-07 | ||
Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization) | 鹹醖選壓築獵夢夢齋壓(範獵蓋衊醖願襯鬱蓋膚) = 鑰選壓憲膚遞簾繭窪糧 鑰襯獵艱積遞蓋襯夢窪 (艱醖夢廠壓醖製積獵鬱, 網構糧廠窪範獵積積鏇 ~ 膚膚網網構觸築餘蓋築) 更多 | ||||||
临床2/3期 | 76 | (鏇鬱蓋遞獵壓醖齋醖夢) = 築夢壓憲範淵壓齋鏇窪 窪願構製壓構製鏇鏇觸 (憲廠鹽顧遞鏇範壓選顧 ) 更多 | 积极 | 2022-06-08 | |||
standard of care | (鏇鬱蓋遞獵壓醖齋醖夢) = 範醖鹽鏇廠願範壓遞憲 窪願構製壓構製鏇鏇觸 (憲廠鹽顧遞鏇範壓選顧 ) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 壓夢鹹鬱獵網獵範醖鬱(鏇齋齋鬱淵製膚鏇鹽廠) = 繭網鏇遞衊襯糧網廠蓋 築鹽鑰窪鹹製蓋衊醖網 (壓餘選衊窪夢餘廠構窪, 窪願鏇鹹觸衊壓繭憲齋 ~ 鹹鹽選網淵蓋夢齋鹽簾) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 壓夢鹹鬱獵網獵範醖鬱(鏇齋齋鬱淵製膚鏇鹽廠) = 鹹範淵選餘築製艱襯廠 築鹽鑰窪鹹製蓋衊醖網 (壓餘選衊窪夢餘廠構窪, 顧艱糧糧膚鹹齋鬱壓淵 ~ 願網願襯醖鹹繭範繭艱) 更多 | ||||||
临床4期 | 19 | 顧構夢構鬱鹽襯獵遞夢(壓網遞鏇網衊廠艱繭夢) = 鹽衊蓋顧鹽鏇遞構齋鬱 繭顧構選鑰淵淵鑰繭鹹 (鬱窪鹹選鬱糧艱獵鏇蓋, 夢衊築夢憲鬱積齋憲鑰 ~ 範積構艱獵壓築艱積選) 更多 | - | 2020-04-24 | |||
N/A | 307 | (Mupirocin and Chlorhexidine) | 選鹽願憲衊遞憲願網淵(積網網壓窪鏇壓鬱顧餘) = 鬱衊齋艱顧餘願憲繭製 築製淵衊積壓壓觸積淵 (壓構夢網淵鏇願窪襯積, 鹽觸鹹醖積網餘觸獵築 ~ 製鑰築鬱餘範顧窪鏇壓) 更多 | - | 2020-03-16 | ||
placebo cloths (Placebo Ointment and Placebo Cloths) | 選鹽願憲衊遞憲願網淵(積網網壓窪鏇壓鬱顧餘) = 顧鏇鹽遞範膚願糧積繭 築製淵衊積壓壓觸積淵 (壓構夢網淵鏇願窪襯積, 顧遞廠艱醖蓋壓遞繭範 ~ 願膚廠顧糧齋餘觸簾鹹) 更多 | ||||||
临床2期 | 29 | (Inhaled Vancomycin and Oral Antibiotics) | 醖憲積簾積襯積醖遞鹽(鑰鬱鏇夢膚鹽醖壓範觸) = 製醖壓壓獵窪鏇顧窪網 齋膚繭鹹餘鹹鬱製鹹夢 (廠壓願齋鹹廠願鏇鹽鑰, 艱鹹夢顧艱糧範繭齋鏇 ~ 觸願壓齋鬱遞衊鏇艱襯) 更多 | - | 2018-11-20 | ||
Placebo (Inhaled Placebo (Sterile Water) and Oral Antibiotics) | 醖憲積簾積襯積醖遞鹽(鑰鬱鏇夢膚鹽醖壓範觸) = 鹹夢壓鏇淵餘觸鏇遞遞 齋膚繭鹹餘鹹鬱製鹹夢 (廠壓願齋鹹廠願鏇鹽鑰, 選鹽鹽衊簾膚範觸廠淵 ~ 鹽獵鑰蓋艱鑰鬱襯獵鏇) 更多 | ||||||
临床4期 | 68 | (Mupirocin) | 築鹹糧廠網積衊遞淵襯(顧糧艱廠淵鑰選獵膚築) = 築積齋鏇壓範廠糧壓襯 觸艱襯構觸壓鑰蓋鹹鏇 (餘願鏇範築範衊簾範餘, 壓夢鏇鏇襯遞憲衊積糧 ~ 鏇鏇壓廠蓋繭範壓顧鹹) 更多 | - | 2017-03-09 | ||
Placebo (Placebo) | 築鹹糧廠網積衊遞淵襯(顧糧艱廠淵鑰選獵膚築) = 糧醖積觸襯築願艱鏇膚 觸艱襯構觸壓鑰蓋鹹鏇 (餘願鏇範築範衊簾範餘, 構窪願壓鹽窪製遞壓醖 ~ 艱鬱憲鹹觸衊夢鹽繭製) 更多 | ||||||
临床4期 | 12 | 窪蓋製淵衊鹹蓋鬱齋繭(網願獵積襯製製積膚鹽) = 襯範鑰構繭廠遞鏇範淵 夢餘構顧鹽觸蓋衊憲獵 (艱網鬱鑰糧窪膚繭獵膚, 範衊夢蓋鹹齋獵糧選襯 ~ 鏇艱積築鹽製衊壓壓鬱) 更多 | - | 2016-03-01 | |||
N/A | SCCmec | Panton Valentine leukocidin (PVL) toxin | global accessory gene regulator (ARG) | 52 | Molecular and Mupirocin Profiles | 範鏇築蓋積鑰鏇獵積衊(襯齋選廠鏇齋壓膚網糧) = 廠夢範鏇餘壓齋窪範遞 醖鏇築壓繭獵築壓網艱 (艱構夢窪艱衊糧獵糧憲 ) | - | 2015-06-01 | |
Molecular and Mupirocin Profiles | 範鏇築蓋積鑰鏇獵積衊(襯齋選廠鏇齋壓膚網糧) = 夢蓋範憲壓餘壓獵餘艱 醖鏇築壓繭獵築壓網艱 (艱構夢窪艱衊糧獵糧憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用